Browse > Article
http://dx.doi.org/10.3345/kjp.2009.52.4.508

A case of fatal pneumococcal 19A meningoencephalitis despite administration of seven-valent pneumococcal conjugate vaccines  

Heo, Ah Rum (Department of Pediatrics, Masan Samsung Hospital, Sungkyunkwan University School of Medicine)
Lee, Jun Hwa (Department of Pediatrics, Masan Samsung Hospital, Sungkyunkwan University School of Medicine)
Publication Information
Clinical and Experimental Pediatrics / v.52, no.4, 2009 , pp. 508-511 More about this Journal
Abstract
Streptococcus pneumoniae is a major cause of serious invasive diseases in children, especially in young infants, but seven- valent pneumococcal conjugate vaccine (PCV7) is believed to prevent invasive pneumococcal pneumonia and meningitis in young children. However, recently, the incidence of non-PCV7 serotype has increased after PCV7 vaccination. A 14-month- old female patient presented at our emergency room with mental change and lethargy. Three days previously, she had developed fever and vomiting. After being admitted, she rapidly progressed to coma and brain death despite prompt and extensive supportive treatment. She expired 20 days after admission with a final diagnosis of pneumococcal 19A (non-PCV7 serotype) meningoencephalitis despite having received PCV7 ($Prevenar^{(R)}$) vaccinations on three occasions. The author reports this first fatality due to pneumococcal 19A meningoencephalitis in Korea and provides a brief review of the literature.
Keywords
Streptococcus Pneumonia Infections; Meningoencephalitis; Serotype 19A;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kaplan SL, Mason EO Jr, Wald ER, Schulze GE, Bradley JS, Tan TQ et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 2004;113:443-9   DOI   PUBMED   ScienceOn
2 Poehling KA, Talbot TR, Griffin MR, Craig AS, Whitney CG, Zell E, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006;295:1668-74   DOI   ScienceOn
3 Choi EH, Kim SH, Eun BW, Kim SJ, Kim NH, Lee JH, et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis 2008;14:275-81   DOI   ScienceOn
4 Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007;297:1784-92   DOI   ScienceOn
5 Munoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia- Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7- valent conjugate vaccine. Clin Infect Dis 2008;46:174-82   DOI   ScienceOn
6 Brueggemann AB, Pai R, Crook DW, Beall B. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog 2007;3:e168   DOI   PUBMED   ScienceOn
7 Bricks LF, Berezin E. Impact of pneumococcal conjugate vaccine on the prevention of invasive pneumococcal diseases. J Pediatr (Rio J) 2006;82(Suppl 3):67-74
8 Pelton SI, Huot H, Finkelstein JA, Bishop CJ, Hsu KK, Kellenberg J, et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007;26:468-72   DOI   ScienceOn
9 Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J 2007;26:123-8   DOI   ScienceOn
10 Jakobsen H, Sigurdsson VD, Sigurdardottir S, Schulz D, Jonsdttir I. Pneumococcal serotype 19F conjugate vaccine induces cross-protective immunity to serotype 19A in a murine pneumococcal pneumonia model. Infect Immun 2003; 71:2956-9   DOI   ScienceOn
11 Von Kries R, Hermann M, Al-Lahham A, Siedler A, Reinert RR. Will the 7-valent pneumococcal vaccine have a similar impact on all invasive pneumococcal infections in children in Germany as in the Kaiser Permanente Trial? Eur J Pediatr 2002;161(Suppl 2:)S140-3   ScienceOn
12 Messina AF, Katz-Gaynor K, Barton T, Ahmad N, Ghaffar F, Rasko D, et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr Infect Dis J 2007;26:461-7   DOI   ScienceOn
13 Centers for Disease Control and Prevention(CDC). Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008;57:144-8   PUBMED
14 Lee CJ, Fraser BA. The structures of the cross-reactive types 19 (19F) and 57 (19A) pneumococcal capsular polysaccharides. J Biol Chem 1980;255:6847-53   PUBMED
15 Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006;368:1495 -502   DOI   ScienceOn
16 Albrich WC, Baughman W, Schmotzer B, Farley MM. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7- valent pneumococcal conjugate vaccine. Clin Infect Dis 2007 ;44:1569-76   DOI   ScienceOn